{
    "clinical_study": {
        "@rank": "158311", 
        "arm_group": {
            "arm_group_label": "ISIS 2503", 
            "arm_group_type": "Experimental", 
            "description": "All patients will begin treatment at a dose of 6 mg/kg/day of ISIS 2503.  ISIS 2503 at the assigned dose will be given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle.  No drug will be administered during the third week of each treatment cycle."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who\n      have advanced cancer of the pancreas."
        }, 
        "brief_title": "ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas", 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the response rate and time to progression in patients with advanced\n      adenocarcinoma of the pancreas who are treated with ISIS 2503. II. Determine the duration of\n      response in these patients receiving this regimen. III. Characterize the safety profile of\n      ISIS 2503 at the recommended phase II dose and schedule in these patients.\n\n      OUTLINE: Patients receive ISIS 2503 IV continuously for 14 days. Treatment continues every\n      21 days for a minimum of 3 courses in the absence of unacceptable toxicity or disease\n      progression.\n\n      PROJECTED ACCRUAL: A total of 14-27 patients will be accrued for this study within 12\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed advanced adenocarcinoma of the pancreas\n        that is considered inoperable Measurable disease with at least 1 lesion measuring at least\n        2 cm in widest diameter identifiable on CT or MRI scan\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:\n        Not specified Hematopoietic: Absolute neutrophil count greater than 1,500/mm3 Platelet\n        count greater than 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL Renal:\n        Creatinine no greater than 2.0 mg/dL Other: Not pregnant or nursing Negative pregnancy\n        test Fertile patients must use effective barrier contraception during and for 6 months\n        after study No underlying disease state associated with active bleeding No active\n        infection requiring therapy No other prior malignancy within the past 5 years except\n        nonmelanoma skin cancer\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy for pancreatic\n        cancer Chemotherapy: No prior chemotherapy for pancreatic cancer except for fluorouracil\n        and/or gemcitabine administered as a radiosensitizer No other concurrent chemotherapy for\n        pancreatic cancer Endocrine therapy: Not specified Radiotherapy: Prior radiotherapy\n        allowed provided indicator lesions not within prior radiation port Recovered from toxicity\n        No concurrent radiotherapy for pancreatic cancer Surgery: See Disease Characteristics\n        Other: No concurrent anticoagulation therapy with heparin No other concurrent approved or\n        experimental cancer therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005594", 
            "org_study_id": "CDR0000067701", 
            "secondary_id": [
                "UAB-9915", 
                "ISIS-2503-CS5", 
                "UAB-F990526011", 
                "NCI-G00-1730"
            ]
        }, 
        "intervention": {
            "arm_group_label": "ISIS 2503", 
            "description": "Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.", 
            "intervention_name": "ISIS 2503", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage III pancreatic cancer", 
            "adenocarcinoma of the pancreas", 
            "stage IV pancreatic cancer"
        ], 
        "lastchanged_date": "December 30, 2010", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UAB-9915"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Norris Cotton Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of ISIS 2503, an Antisense Inhibitor of H-Ras, in Patients With Advanced Pancreatic Cancer", 
        "overall_official": {
            "affiliation": "University of Alabama at Birmingham", 
            "last_name": "James A. Posey, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2000", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The primary outcome measure of this study is to estimate the response rate and observe the time to tumor progression of the patients treated on this study.", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005594"
        }, 
        "responsible_party": {
            "name_title": "James Posey, MD/ Principal Investigator", 
            "organization": "University of Alabama at Birmingham"
        }, 
        "secondary_outcome": {
            "measure": "Determine the duration of response in responding patients. Further characterize the safety profile of ISIS 2503 at the recommended dose and schedule.", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "source": "University of Alabama at Birmingham", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Isis Pharmaceuticals", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Alabama at Birmingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2000", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2010"
    }, 
    "geocoordinates": {
        "Norris Cotton Cancer Center": "43.642 -72.252", 
        "University of Alabama Comprehensive Cancer Center": "33.521 -86.802"
    }
}